Researchers at the National Institutes of Health have identified the biological mechanisms behind weight-loss plateaus in patients taking semaglutide-based medications like Ozempic and Wegovy. The groundbreaking study analyzed brain imaging data from 284 patients over 18 months, revealing that prolonged medication exposure triggers receptor desensitization in the hypothalamus—the brain region controlling hunger and appetite.
Dr. Sarah Chen, lead researcher at the NIH National Institute of Diabetes and Digestive and Kidney Diseases, found that individual brain cell sensitivity varies significantly between patients, explaining why some maintain weight loss while others experience regain. The research demonstrates that semaglutide activates GLP-1 receptors differently across populations, with approximately 40% of patients showing reduced medication responsiveness over time.
These findings open new avenues for personalized obesity treatment and suggest potential interventions to extend medication effectiveness. Understanding the neural basis of treatment resistance could lead to optimized dosing strategies and combination therapies for improved long-term outcomes.
Was this article helpful?
